Create a free research account to view current pricing and place an order.
Mechanism of action
Semaglutide is a long-acting GLP-1 receptor agonist. GLP-1 receptor activation enhances glucose-dependent insulin secretion, suppresses glucagon release, delays gastric emptying, and engages central appetite-regulation pathways within the hypothalamus and brainstem.
Half-life & pharmacokinetics
Half-life: Approx. 1 week.
Approximate half-life is about 1 week. Peak concentration is typically reached 1-3 days after subcutaneous administration, and steady state is generally approached after 4-5 weeks of once-weekly use.
Research dosing reference
0.25-2.4 mg once weekly; escalate only after GI tolerance is established.
Dose interpretation (U-100 units)
| Target dose | U-100 units |
|---|---|
| 0.25 mg | 5 units |
| 0.50 mg | 10 units |
| 1.00 mg | 20 units |
| 2.40 mg | 48 units |
Units are concentration-specific - confirm against your actual reconstitution volume.
Reconstitution & concentration
| Vial | Preferred reconstitution | Final concentration |
|---|---|---|
| 10 mg | 2 mL BAC Water | 0.050 mg/unit |
Injection timing
Once weekly on a consistent day. Time of day is less important than consistency; choose timing that minimizes nausea disruption.
Beginner escalation
Start at the lowest practical exposure and hold each step long enough to evaluate GI tolerance before increasing.
Side-effect mitigation
Monitor nausea, reflux, constipation, reduced appetite, hydration status, fatigue, and delayed gastric emptying. Slow escalation and hydration/electrolytes are primary mitigation tools.
Stack compatibility
Avoid stacking overlapping incretin agonists unless intentionally structured and clinician supervised. Pathway contrast with GH-axis, mitochondrial, or lipolysis adjuncts is generally cleaner than incretin overlap.
Storage & stability
Lyophilized: refrigerated or controlled cool storage. Reconstituted: refrigerated, protected from heat/light, and handled aseptically.
Protocol duration & reassessment
Long-term metabolic protocols should include reassessment every 8-12 weeks: GI tolerance, hydration, appetite adaptation, body-composition response, metabolic markers, and whether escalation is still needed. Avoid continuous escalation without objective review.
Frequently asked questions
What is Semaglutide and how does it work?
Semaglutide is a long-acting GLP-1 receptor agonist. GLP-1 receptor activation enhances glucose-dependent insulin secretion, suppresses glucagon release, delays gastric emptying, and engages central appetite-regulation pathways within the hypothalamus and brainstem.
What is the half-life of Semaglutide?
Semaglutide: Approx. 1 week. Approximate half-life is about 1 week. Peak concentration is typically reached 1-3 days after subcutaneous administration, and steady state is generally approached after 4-5 weeks of once-weekly use.
How is Semaglutide reconstituted for research?
Preferred reconstitution for the 10 mg vial is 2 mL BAC Water, giving 0.050 mg/unit. Always confirm concentration math before any use. Research use only.
Is Semaglutide FDA approved?
No. Semaglutide is an investigational research-use-only compound - not for human or animal consumption and not FDA approved.
Semaglutide product overview · Semaglutide cost · All research reference · Research guides
External references: Peptide (Wikipedia) · U.S. Food and Drug Administration